Financial PerformanceVirbac published its 1Q25 sales figures, which came in at €375m, perfectly in line with expectations and marks organic growth of +4.9%.
Growth OpportunitiesExposures to emerging countries like India and Mexico are enabling an acceleration in the group's growth pace as the growing middle class in these countries and their purchasing power are fuelling the animal health sector.
Market PositionThe group's product and geographic mix should enable it to continue to slightly outperform its market for a few more years.